Immix Biopharma, Inc.
IMMX
$8.21
$0.202.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.70M | 12.14M | 12.02M | 11.75M | 11.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.96M | 24.05M | 23.78M | 21.77M | 22.67M |
| Operating Income | -29.96M | -24.05M | -23.78M | -21.77M | -22.67M |
| Income Before Tax | -29.40M | -23.53M | -23.09M | -20.87M | -21.66M |
| Income Tax Expenses | 37.70K | 37.20K | 40.60K | 42.00K | 41.00K |
| Earnings from Continuing Operations | -29.44 | -23.56 | -23.13 | -20.91 | -21.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | 12.90K | 85.00K |
| Net Income | -29.44M | -23.56M | -23.13M | -20.90M | -21.61M |
| EBIT | -29.96M | -24.05M | -23.78M | -21.77M | -22.67M |
| EBITDA | -29.71M | -23.84M | -23.66M | -21.70M | -22.64M |
| EPS Basic | -0.88 | -0.77 | -0.78 | -0.71 | -0.78 |
| Normalized Basic EPS | -0.55 | -0.48 | -0.49 | -0.44 | -0.49 |
| EPS Diluted | -0.88 | -0.77 | -0.78 | -0.71 | -0.78 |
| Normalized Diluted EPS | -0.55 | -0.48 | -0.49 | -0.44 | -0.49 |
| Average Basic Shares Outstanding | 131.84M | 121.18M | 118.67M | 117.47M | 111.21M |
| Average Diluted Shares Outstanding | 131.84M | 121.18M | 118.67M | 117.47M | 111.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |